The role of Dendritic Cells (DC) in cell-mediated immunity has been extensively investigated [1] [2] [3] [4] [5] . DCs have been found to play a central role in the induction of antitumor immunity in tumor-bearing host by a process of antigenic cross-presentation and have displayed activity in NSCLC [6] . They efficiently display antigens on major histocompatibility complexes (MHC II) ultimately stimulating proliferation and activation of CD4+ and CD8+ T cells. CD 4+ cells further augment the activity of natural killer cells and macrophages, in addition to amplifying antigen-specific immunity by local secretion of cytokines [7] [8] [9] [10] [11] . These attributes make DCs a central component in therapeutic strategies of many current immune based therapies in NSCLC.
Despite progress made in understanding the molecular biology behind carcinogenesis and advancements in our technical proficiency clinical application of immune based cancer vaccines have yielded modest results. There are several hypotheses to explain potential lack of activity, including ineffective priming of tumor-specific T cells, lack of highavidity of primed tumor-specific T cells, and physical or functional disabling of primed tumor-specific T cells by the primary host and or tumor-related mechanism. For example in NSCLC a high proportion of the tumor-infiltrating lymphocytes are immunosuppressive T regulatory cells (CD4+ CD25+) that secrete transforming growth factor-β (TFG-β) and express a high level of cytotoxic T lymphocyte (CTL) antigen-4 [12, 13] . These cells have been shown to impede immune activation by facilitating T cell tolerance to tumor associated antigens rather than cross-priming CD 8+ T cells resulting in the nonproliferation of killer T cells that recognize the tumor and will not attack it [12] [13] [14] [15] [16] [17] [18] . Elevated levels of IL-10 and TFG-β are found in patients with NSCLC. Animal models have shown immune suppression is mediated by these cytokines serving as a defense for malignant cells against the body's immune system [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] .
As our understanding of the pathogenesis of cancer steadily evolves researchers are continuously developing novel therapies designed to overcome each new challenge. This chapter will discuss recent vaccine therapeutic strategies in lung cancer focusing on clinical trials that have contributed to our overall understanding of the immune system and its utilization in the treatment of lung cancer.
Non-Small Cell Lung Cancer Cellular Vaccines

Lucanix ™
Lucanix™ is a non-viral gene-based allogeneic vaccine that incorporates the TFG-β2 antisense gene into a cocktail of four different NSCLC cell lines [29] . Elevated levels of TFG-β2 are linked to immunosupression in cancer patients [30] [31] [32] [33] [34] [35] (Table 2 and 
GVAX ® Lung
Given the histological heterogeneity of NSCLC and the relative absence of information on the relevant immunodominant antigens in this disease, in initial trials autologous tumor cells were selected as the source of tumor antigens in NSCLC [55] . The first pilot study of autologous GVAX ® Lung conducted by Glenn Dranoff at the Dana-Faber cancer institute using a first generation adenoviral vector and recombinant human GM-CSF [56] . The most common vaccine-related adverse events were local vaccine injection site reactions (93%) followed by fatigue (16%) nausea (12%) and pain, arthralgia, and upper respiratory infection (each at 5%). Two grade 4 (pericardial effusion) and six grade 3 (dyspnea, fatigue, injection site reaction, hypokalemia, malignant ascites, and pulmonary embolism) possibly related events were reported. There was no association between vaccine dose and the total number of adverse events or grade 3 and 4 adverse events. Table 2 However, objective tumor responses were not seen despite a 25-fold higher GM-CSF secretion concentration with the bystander GVAX ® vaccine (Table 2 and 3 ). The frequency of vaccine site reactions, tumor response, time to progression and survival were all less favorable to autologous GVAX ® , although results were similar to historical cytotoxic therapy for second line NSCLC.
Overall, these results suggest that autologous malignant tissue transfection with adenovirus-delivered GM-CSF is superior to the bystander approach, despite variability of GM-CSF expression levels and practical limitations inherent to surgically harvested tumor tissue.
L523S Vaccine
L523S is a lung cancer antigen originally identified through screening of genes differentially expressed in cancer cells versus normal tissue [59, 60] . L523S is shown to be expressed in approximately 80% of NSCLC cell lines [59, 60] . In preclinical studies the immunogenicity of L523S in humans was initially shown by detecting the presence of existent antibody and CD4+ T cell responses to L523S in patients with lung cancer.
Subsequent studies further validated L523S's immunogenicity demonstrating that human
CTLs could specifically recognize and kill cells that express L523S. It has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) and when delivered by E1B-deleted adenovirus (Ad/L523S).
A phase I clinical trial of 13 stage IB, IIA, and IIB NSCLC patients was conducted using a prime/boost vaccination strategy first with pVAX/ L523S at a dose of 8 mg on days 0 and 14 then Ad/ L523S at three dosing cohorts of 1, 20, and 400 x10 9 viral particles on days 28 and 56 (Table 2 and A total of 18 patients received at least one full course (three vaccinations) of treatment.
One patient was removed before the completion of the first course due to a serious adverse event not associated with the vaccine. Three more patients experienced serious adverse events, which were also not associated with the vaccine. Side effects associated with the vaccine included minimal skin erythema in four of the patients (Table 2 and 3 ).
All but one patient had a measurable CD8+ response after three vaccinations. There was no statistically significant difference in CD8+ response depending in weather or not the patients were HLA matched. One patient showed a partial response for 13 months and 5 patients had stable disease ranging from 1.6 to > 52 months [69, 70] . Based on the six surviving patients, the tumor vaccine appears to elevate immune response for at least 150
weeks. Overall, the Kaplan-Meier estimate for the survival of 19 patients was 18 months.
One-year survival was estimated at 52% (Table 2 and 3) . The low toxicity and good survival in this study suggested benefit from clinical vaccination. Further clinical investigation is on going.
Non-small Cell Lung Cancer Subunit Vaccines L-BLP-25 Liposomal Vaccine
Mucin (MUC) 1 is a high molecular weight integral membrane protein on the apical surface of mucin-secreting epithelial cells. The extracellular domain of MUC1 contains a heavily glycosylated peptide core composed of a tandemly repeating sequence of 20 amino acids [71] . It is expressed in many cancers, including NSCLC [72] . Although the MUC1 glycoprotein is expressed on the cell surface of many normal epithelial tissues and carcinomas, it has been selected as a target due to its high levels of overexpression and aberrant glycosylation patterns on carcinoma cells over normal cells, thereby conferring potentially high immunogenicity [73] . Recent studies have identified that MUC1 is associated with cellular transformation, as demonstrated by tumorigenicity [74] , and can confer resistance to genotoxic agents [75] . 
EP2101
EP2101 is a peptide-based vaccine designed to induce CTLs directed against carcinoembryonic antigen (CEA), p53, HER-2/neu and melanoma antigen E (MAGE)-2/3-tumor associated antigens [79] [80] [81] [82] [83] [84] [85] [86] [87] . These are frequently overexpressed in NSCLC.
Analogue peptides have been shown to be capable of generating CTLs that are able to recognize wild-type epitopes expressed on tumor cell lines [88] [89] [90] . EP2101 has demonstrated immunogenicity in HLA-A2.1/k transgenic mice models [91] [92] [93] . It completed [94] [95] [96] . Results from these demonstrated that vaccination with EGF is immunogenic and appears to be well tolerated.
In one trial, 43 patients with stage IIIB or IV NSCLC randomly received either a single or double dose [94] . The patients were given four weekly dosed followed by monthly immunizations. Side effects were mild to moderate, including mainly fever (42%), chills (47%), nausea (44%), vomiting (40%), tremors (44%), anorexia (35%) and pain (49%).
Slightly higher toxic percentages were seen in the patients who received double dosages of the vaccine (Table 2 No patients experienced severe toxicity. Side effects consisted of grade 2 fever, chills, nausea, vomiting, nausea, hypertension, head ache, dizziness, flushing, pain at the injection site, bone pain, mouth dryness and hot flashes ( Table 2 and 3 ).
The combined data of the two Gonzalez trials suggested that higher antibody responses were obtained when the vaccine was emulsified in montanide ISA 51 or when low-dose cyclophosphamide was administered before the vaccination; however, due to the small sample size, the difference was not statistically significant. Percentages of GAR were significantly higher when montanide ISA 51 was used as an adjuvant in both trials compared with alum groups. More than 90% of all vaccinated patients were seroconverted and GAR was achieved by approximately 50% of vaccinated patients.
Median survival of GAR patients was 9.1 months, whereas poor antibody responding patients had survival of 4.5 months. The median survival of all vaccinated patients was 8.2 months. In addition, patients with ≥ 60 days response duration showed a significant increase in survival times compared with the corresponding groups with < 60 days response duration (Table 2 and 3) . These data as well as the recent approval of EGFR inhibitors gefitinib and erlotinib justify further investigation in targeting EGF by vaccination strategy.
Melanoma-associated Antigen E-3vaccine (MAGE-3)
MAGE-AE is a 361 amino acid protein which belongs to the category of cancer/testis tumor antigens. In normal tissue MAGE-3 is expressed only by testicular germ cells, however, it is aberrantly expressed in a wide variety of tumors, including about 35% of NSCLC [98] . Several CD8+ T cell epitopes of MAGE-3 have been identified in vitro [88, 89, [99] [100] [101] [102] [103] [104] [105] , including HLA-A1-restricted epitope 168-176 [106] and HLA-A2-restricted epitope 271-279 [107] . Based on these findings, synthetic peptides corresponding to these epitopes have been introduced into clinical vaccination studies in which they were associated with regression of melanoma in individual cases [108] . 
Transcriptase catalytic subunit antigen vaccine
It has been established that human T cells recognize telomerase as a tumor associated antigen [110] [111] [112] [113] . Although telomerase is also expressed in some normal tissue, such as bone marrow, and in crypts of the gastrointestinal epithelium [114] , it is highly expressed in a vast majority of cancer cell lines. GV1001 is a unique peptide corresponding it a sequence of transcriptase catalytic subunit human telomerase reverse transcriptase (hTERT) derived from its active site. It contains the 611 -626 sequence of hTERT and is capable of binding to molecules encoded by multiple alleles of all three loci of HLA class II [115] . HR2822, is a second peptide corresponding, to sequences 54 -548 of hTERT.
Brunsvig et al. [116] initiated a phase I/II trial of GV1001 (112 mg Twenty-four of 26 patients enrolled were considered evaluable having received a minimum of four weeks of treatment. Fourteen patients completed the study while 10 patients were taken off study due to disease progression. Eleven patients demonstrated an immune response against GV1001, and 2 patients demonstrated a response to HR2822.
After receiving booster vaccinations, two additional patients converted to immune responders. One patient with stage IIIA NSCLC had a complete response and developed GV1001-specific CTLs that could be cloned from peripheral blood. The median survival time for all 26 patients was 8.5 months (Table 2 and 3 ). This trial demonstrated GV1001
and HR2882 to a lesser extent are immunogenic targets and warrant further investigation.
Dexosomes
Dexosomes are dendritic cell-derived lipid vesicles that express high levels of a narrow spectrum of cell proteins, which have been shown to play a role in the activation of immune response [117] [118] [119] [120] [121] . In vitro, dexosomes have the capacity to present antigen to naïve CD8+ cytotoxic T cells and CD4+ T cells [117, 122] . Purified dexosomes were shown to be effective in both suppressing tumor growth and eradicating an established tumor in murine modles [119] . Morse et al. [123] Expression of agal epitopes after gene transfer of agal (using retroviral vector) in human A375 melanoma cells prevented tumor formation in nude mice [124] .
Preliminary results by Morris et al. [125] using three irradiated lung cancer cell lines genetically altered to express xenotransplantation antigens by retroviral transfer of the murine agal gene, were recently described in seven patients with stage IV, recurrent or refractory NSCLC. Intradermal injections were given at doses of 3x10 6 , 10x10 6 , 30x10 6 or 100x10 6 cells/vaccine once every four weeks spanning a total of 4 doses. Only 4 patients received all 4 vaccinations, 2 patients received three vaccinations, and one patient received two vaccinations at the abstract was published. Toxicity involved grade 1 and 2 pain at the injection site, local skin reactions, fatigue, and hypertension. Four patients had stable disease for > 16 months (Table 2 and 
Dendritic Cell Vaccines
DCs are potent antigen-presenting cells [1] [2] [3] [4] [5] . As part of a phase II study Hirshowitz et al. [6] recently produced a DC vaccine from CD14+ precursors, which were pulsed with apoptotic antibodies from an allogeneic NSCLC cell line that overexpressed Her2/neu, CEA, WH1, MAGE-2, and survivin. A total of 16 patients with stage IA to IIIB NSCLC were vaccinated. The patients were immunized twice, one month apart.
There were 10 patients who experienced skin reaction at the injection site ad 4 patients experienced minor fatigue. No patients experienced a serious adverse event. Five patients showed no antigen-independent response and six patients showed an antigen-specific response (Table 2 and 3 ). The study concluded that the vaccine was safe and demonstrated immunologic activity. Further work is ongoing.
Cyclophilin B
Cyclophilin-B (CypB) is a ubiquitous protein playing an important role in protein folding [126, 127] , and is expressed in both normal and cancerous cells. CypB- respectively. Overall survival for NSCLC patients receiving CypB or modified CypB vaccine was 67+ and 28+ weeks, respectively (Table 2 and 3) . One patient with SCLC was not evaluable for response.
Small Cell Lung Cancer Fucosyl GM-1
The ganglioside fucosyl-GM1 is a carbohydrate molecule present in most cases of SCLC [130, 131] , but absent in normal lung tissue. Immunostaining has demonstrated the presence of fucosyl-GM1 in culture media from SCLC cell lines, in tumor extracts and in serum of mouse xenografts [132] . Fucosyl-GM1 was detected in the serum of 4 of 20 SCLC patients with extensive-stage disease, but was not present in the serum of 12 patients with non-SCLC or in 20 healthy volunteers [132] . The specificity of fucosyl-GM1 to SCLC makes it a potential target for immunotherapy.
Dickler et al treated 13 patients were with Fuc-GM1 isolated from bovine thyroid tissue; 10 patients completed the study and were evaluable [133] . IgM levels. The IgM titers for patients receiving 30μg or 10μg doses were similar to levels reached with patients treated with bovine fucosyl-GM1, while Ig-G levels were lower. Toxicities were minimal and included injection-site reaction, mild flu-like symptoms, myalgias, and sensory neuropathy (19%) ( Table 4 and 5).
BEC2
Ganglioside GD3 is a cell surface glycosphingolipid whose expression in normal tissue is limited to cells of neuroectodermal origin and a subset of T lymphocytes [135] [136] [137] .
High levels of expression have been demonstrated in SCLC tumors and cell lines [138] .
Because GD3 is present at low levels in normal tissues, it is poorly immunogenic. BEC2, an anti-idiotypic IgG2b mouse antibody that is structurally similar to GD3, demonstrates strong immunogenic properties in patients with melanoma [139] . antibody production one year following treatment. Median survival was 20.5 months from diagnosis, and patients with measurable anti-GD3 antibodies showed the longest relapse-free intervals (Table 4 and 5) . When compared to SCLC patients treated with conventional therapy alone, the authors found patients treated with BEC2 vaccine to have longer than expected survival time, though not statistically significant. Significant toxicity was minimized to local skin irritation. There was no evidence of toxicity related to normal tissue destruction, despite the fact that GD3 is expressed by some normal tissues.
PolySA
Polysialic acid (polySA) is found on the surface of Gram-negative bacteria (such as group B meningococcus), embryonic neural crest cells, and some malignancies of neural crest origin [141, 142] . The large size and negative charge of this molecule inhibit binding of cell adhesion molecules, and it is this property that is believed to contribute to its role in neural crest cell migration and early metastasis of malignant cells [143, 144] .
PolySA has been shown to be expressed abundantly by SCLC tissues [145] [146] [147] , making it a potentially viable target for SCLC vaccine therapy.
Krug et al investigated the immunogenicity of polySA vaccination in 11 SCLC patients following conventional therapy [148] . Two forms of polySA were administered to patients. 5 patients received vaccination with polySA, and 6 patients received polySA manipulated by N-propionylation (NP-polySA), which has been shown to boost the IgG response in mice [149] . (Table 4 and 5). Four patients reported sensory neuropathy.
p53
The tumor suppressor gene p53 plays a key role in cell cycle regulation, and is mutated in 90% of SCLC [150, 151] . In normal tissue, the p53 protein is present in low levels because of its brief half-life. Mutant p53 in cancer cells has a prolonged half-life and is therefore present at much higher levels in these tissues. When induced, anti-p53 cytotoxic lymphocytes attack tumor tissues while sparing normal tissue in preclinical studies [152] [153] [154] .
Dendritic cells activated by p53-producing adenovirus were administered to 29 patients with extensive-stage SCLC [155] . 57.1% of patients showed significant p53-specific immune responses (Table 4 and 
WT1
The Wilms' tumor gene (WT1) is responsible for Wilms' tumor, a pediatric renal cancer, and encodes a protein involved in cell proliferation and differentiation, apoptosis, and organ development [156] [157] [158] . WT1 is overexpressed in several hematological malignancies as well as various solid tumors, including lung, breast, thyroid and colorectal cancers [159, 160] . WT1-specific cytotoxic lymphocytes (CTL) lyse WT1 expressing tumor cells in vitro without damaging normal tissues that express WT1
physiologically [161, 162] .
Oka et al treated 26 patients, including 10 lung cancer patients (histological type not specified), with WT1 vaccine following completion of conventional therapy [163] . Three patients showed decreased serum levels of tumor markers (CEA or SLX) following vaccination; one patient also showed a decrease in tumor size radiographically. One patient had stable disease at followup; four patients developed progressive disease, and 2
were unevaluable. Three patients demonstrated increased activity of WT1-specific CTL activity. A correlation (P=0.0397) between immunological and clinical response was observed for all study patients. Toxicities were limited to injection-site inflammation.
Despite the fact that WT1 is expressed in many normal tests, routine laboratory investigates did not reveal damage to these tissues following vaccine administration.
Discussion
The poor overall survival of patients with advanced lung cancer combined with the and MAGE-A3 in particular has lead to the conduct of phase III trials and the data generated from these trials will potentially serve to guide direction of these novel therapeutic modalities over the next several years. Yet more remains to be discovered.
This chapter summarizes the current evidence of the clinical activity of immune-based vaccines in lung cancer. Through enhancement of tumor antigen recognition and immune activation these vaccines may one day provide patients with a highly tolerable therapy to use in combination with traditional approaches. However, this treatment strategy is relatively new and will require continued development in order to determine its ultimate role in the treatment of lung cancer. 
